Trials / Completed
CompletedNCT00455351
Vorinostat and Palliative Radiotherapy
Phase I Study on Suberoylanilide Hydroxyamic Acid (Vorinostat) a Histone Deacetylase Inhibitor, in Palliative Radiotherapy for Advanced Tumors.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Oslo University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
Phase I study. Side-effects when combined with standard palliative radiotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vorinostat | Increasing dosing, phase I |
Timeline
- Start date
- 2007-02-01
- Primary completion
- 2009-03-01
- Completion
- 2009-08-01
- First posted
- 2007-04-03
- Last updated
- 2023-05-08
Locations
1 site across 1 country: Norway
Source: ClinicalTrials.gov record NCT00455351. Inclusion in this directory is not an endorsement.